Dr. Usmani on Optimizing Treatment Selection in Relapsed/Refractory Multiple Myeloma

April 16, 2021
Saad Z. Usmani, MD, FACP

Partner | Cancer Centers | <b>Atrium Health Levine Cancer Institute</b>

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Some factors to consider for treatment selection include patient preference, prior therapies, prior responses, and toxicities, says Usmani. Additionally, understanding the pattern of the patient’s relapse and whether they are having a slow biochemical relapse or an aggressive relapse with high-risk features is important, Usmani explains.

In terms of therapy selection, a key consideration is whether the patient is refractory to lenalidomide (Revlimid), says Usmani. Currently, lenalidomide-based and non–lenalidomide-based triplet regimens are available for the treatment of patients with relapsed/refractory multiple myeloma, Usmani says.

Taking these factors into consideration can help optimize treatment selection for these patients, concludes Usmani.